Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Here’s What Happened

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped down prior to trading on Monday . The stock had previously closed at $52.6840, but opened at $49.0692. Zealand Pharma A/S shares last traded at $49.0692, with a volume of 100 shares trading hands.

Wall Street Analyst Weigh In

A number of research firms recently commented on ZLDPF. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday. Berenberg Bank downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Zacks Research cut shares of Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a research report on Thursday. Finally, Jefferies Financial Group downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Zealand Pharma A/S Stock Performance

The company has a debt-to-equity ratio of 0.02, a current ratio of 37.17 and a quick ratio of 37.17. The stock has a fifty day simple moving average of $45.69 and a two-hundred day simple moving average of $49.36. The firm has a market capitalization of $3.51 billion, a P/E ratio of 8.14 and a beta of 0.88.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.